葡萄糖激酶激活剂及其新药多格列艾汀在2型糖尿病中的研究进展

Research Progress of Glucokinase Activator and Its New Drug Dorzagliatin in Type 2 Diabetes Mellitus

在人口老龄化日益严重的今天,2型糖尿病的发病率和患病率呈逐年上升趋势,并有年轻化趋势。2型糖尿病及其并发症对患者自身、家庭及社会都带来了严重的心理及经济负担。多格列艾汀(Dorzagliatin)是即将推出的糖尿病创新口服药物,为一种全新的葡萄糖激酶激活剂,并以葡萄糖激酶作为2型糖尿病的新靶点。该药物通过修复2型糖尿病患者血糖传感器中葡萄糖激酶的作用来重塑机体血糖稳态,以实现2型糖尿病治疗。

In today´s increasingly serious population aging,the incidence and prevalence of type 2 diabetes are increasing year by year,and there is a younger trend.Type 2 diabetes and its complications have brought serious psychological and economic burdens to patients themselves,their families and society.Dorzagliatin,an upcoming innovative oral drug for diabetes,is a novel glucokinase activator,and takes glucokinase as a new target for type 2 diabetes.The drug reshapes the body´s blood glucose homeostasis by restoring the role of glucokinase in the blood glucose sensor of type 2 diabetic patients to achieve type 2 diabetes treatment.